What Araceli Biosciences does

Araceli Biosciences is a private life-sciences instrumentation company that develops high-content imaging (HCI) platforms for drug discovery, biomarker research, and preclinical development. Founded in 2021 as a spinout from Phoseon Technology and headquartered in Tigard, Oregon, the company sells the Endeavor portfolio—a family of four instruments (Core, Pro, Ultra, and Live Cell) covering 96-, 384-, and 1536-well plate formats, with the flagship Ultra capturing a full 1536-well plate in under 4 minutes and supporting 280+ plates per day at 0.27 µm/pixel submicron resolution. The hardware is differentiated by a proprietary laser autofocus system (0.2% out-of-focus well rate), a custom 1.1" sCMOS camera, SiLA 2.0 automation compatibility, and—in the Live Cell tier—an Okolab-integrated stage-top incubation chamber for kinetic imaging with sub-4-minute 1536-well acquisition. The instruments are paired with EndeavorOS acquisition software, ClaireRT real-time assay monitoring, and Clairvoyance AI-powered image analysis, with open-ecosystem compatibility with CellProfiler and integration partnerships with ViQi for predictive phenotyping.

The company generates revenue primarily through capital equipment sales (Core starting at $225k; Pro/Ultra quote-based), supplemented by extended warranty and service plans, on-site and remote training, and a planned expansion into reagents and consumables. Go-to-market is a direct enterprise field-sales model targeting pharmaceutical and biotechnology companies (primary), academic and government screening centers, and contract research organizations, supported by regional demo sites in Oregon, California, Boston, and Europe, a dedicated EU Business Development Manager, and a content-driven demand generation engine (ScienceIRT podcast, application notes, posters). As of 2026 the company has secured reference customers including Idorsia Pharmaceuticals (EU commercial anchor), VALID Therapeutics (AI-driven iPSC drug discovery), Max Planck COMAS, and the UF Scripps HTS Center, and has closed approximately $25M+ in cumulative funding across a $11.2M seed round (April 2025) and an ongoing ~$14M exempt offering.

Name

Araceli Biosciences

Legal name

Araceli Biosciences Inc.

Website

https://aracelibio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Araceli Biosciences develops ultra-fast high-content imaging platforms (Endeavor portfolio) for pharmaceutical, biotech, academic, and CRO customers engaged in drug discovery and high-throughput screening. The company sells capital equipment paired with AI-powered image analysis software (Clairvoyance) and real-time assay monitoring (ClaireRT).

Ownership category

akta.pro rank

Product category

High-Content Imaging Systems

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• High content imaging
• Drug discovery tools
• AI image analysis
• High throughput screening
• Laboratory automation

Headquarters

HQ city

Tigard

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. High-Content Imaging Hardware Sales: Sale of Endeavor imaging instruments (Core, Pro, Ultra tiers) as capital equipment. Hardware is sold as a one-time capital purchase with optional extended warranty and service plans. Starting prices are publicly disclosed for Core ($225k-$250k). Pro and Ultra pricing is quote-based. Storage/NAS solutions sold separately as add-on.
2. Software Licenses and Subscriptions: EndeavorOS acquisition software ships with hardware. Clairvoyance analysis software ships with all Endeavor systems. Storage sold separately (Clairvoyance workstation includes 2TB local storage; NAS options available). Service plans and extended warranties provide ongoing revenue.
3. Service, Support, and Training: 1-year manufacturer warranty included with all systems. Optional Extended Warranty & Service Plans covering hardware, parts, labor, on-site dispatch, scheduled preventive maintenance, software updates, and priority support. On-site and remote training sessions, application-focused sessions, and optional consulting for assay optimization/automation are additional service offerings.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Araceli Biosciences develops and sells the Endeavor portfolio of ultra-fast high-content imaging instruments (Core, Pro, Ultra, and Live Cell) for pharmaceutical and biotech drug discovery workflows. The instruments are paired with proprietary software (EndeavorOS acquisition, ClaireRT real-time monitoring, and Clairvoyance AI-powered image analysis) and support 96, 384, and 1536-well plate formats with submicron resolution. The platform also integrates with lab automation systems via SiLA 2.0 and Okolab incubation for live cell kinetic imaging.

Product overview

Araceli Biosciences offers the Endeavor portfolio of high-content imaging platforms designed for ultra-high-throughput drug discovery workflows. The portfolio consists of four instrument tiers: Endeavor Live Cell (live cell kinetic imaging with Okolab incubation), Endeavor Ultra (fastest model, sub-4 min/1536-well), Endeavor Pro (mid-throughput workhorse, 6 min/plate), and Endeavor Core (accessible entry point, 22 min/plate, starting at $225k). All instruments share EndeavorOS acquisition software and are supported by Clairvoyance AI-powered analysis software and ClaireRT real-time monitoring (add-on for Ultra). The platform delivers submicron resolution (0.27 µm/pixel) across 96, 384, and 1536-well formats, with throughput up to 1.5x greater than industry standard.

Differentiator

Problem solved

Functional benefit

Brands

• Endeavor: High-content imaging platform portfolio including Endeavor Ultra, Pro, and Core models for ultra-high-throughput screening
• Clairvoyance
• EndeavorOS
• ClaireRT
• Endeavor Live Cell

Products and services

• Endeavor Live Cell The fastest high-content imaging platform available for live cell imaging, enabling full-plate acquisitions of time-series that capture rapidly occurring biological changes. Features sub-4-minute acquisition of 1536-well plates, submicron resolution (0.27 µm/pixel), and Okolab stage-top incubation with CO2 and temperature control for precise environmental conditions.
• Endeavor Ultra The fastest high-content imaging platform in the Endeavor portfolio, delivering 1536-well plate acquisitions in under four minutes with submicron resolution and full-well coverage. Capable of imaging more than 280 plates per day at subcellular detail. Includes ClaireRT real-time assay monitoring.
• Endeavor Pro High-throughput screening engine optimized for 96, 384, and 1536-well formats with automation-ready design. Delivers 6-minute acquisition time per 1536-well plate and integrates seamlessly into modern workflows for consistent daily performance in drug discovery screening.
• Endeavor Core Accessible high-performance high-content imaging platform starting at $225,000. Equipped with EndeavorOS acquisition software and designed for assay development and small-to-mid-scale screening workflows. Features 22-minute acquisition time per 1536-well plate with maximized well coverage.
• ClaireRT Real-Time Assay Monitoring Real-time assay monitoring software that detects focus and assay variability during acquisition to reduce reruns and ensure reliable data from every plate. Available as a standard feature on Endeavor Ultra and as an add-on for Pro and Core tiers.

Quantifiable outcome

• Imaging speed increased by up to 12x vs. industry standard, with 94.9% reduction in acquisition time demonstrated in cell painting assays at Max Planck
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability2 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• OkolabcoreTechnology or Integration · 20 May 2026Okolab contributed live cell incubation and environmental control expertise to the Endeavor Live Cell platform. Custom Okolab stage-top incubation chamber engineered to support Endeavor's imaging speed and quality, featuring heated chamber with motorized lid and in-chamber temperature, gas, and humidity sensors. Partnership enabled sub-4-minute 1536-well live cell acquisition with precise environmental control.
• ViQi InccoreTechnology or Integration · 18 April 2025ViQi and Araceli Biosciences integrated ViQi's AI-powered image analysis technology with Araceli's ultra-fast Endeavor imaging platform. The collaboration enhances AI-driven phenotypic profiling in high-throughput cell-based assays. ViQi's AVIA (Automated Viral Infectivity Assay) and AutoHCS platforms complement Endeavor's high-speed data generation. Joint application note published demonstrating phenotypic profiling of antivirals using ViQi's predictive AI analytics powered by Endeavor data.
• VALID TherapeuticscoreStrategic or Co-development Partner · 22 January 2025VALID Therapeutics partnered with Araceli Biosciences to leverage the Endeavor Ultra High Throughput High Content Imaging Platform for AI-driven drug discovery using complex human iPSC co-culture models. The partnership enables VALID to generate high-quality, actionable data at unprecedented speed and scale. VALID's CEO noted the Endeavor platform delivers exceptional performance and usability for arrayed formats, with Araceli's expertise being critical for AI-ready data generation.
• Max Planck Institute for Molecular Physiology (COMAS)minorStrategic or Co-development PartnerCollaboration with Max Planck Institute's Compound Management and Screening Center (COMAS) for cell painting assay validation. COMAS used Endeavor to demonstrate 94.9% reduction in imaging time vs. their previous system. The collaboration produced published scientific posters and application notes validating Endeavor performance across 41 384-well plates.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Others

• ViQi Inc: AI-powered image analysis provider partnered with Araceli; complementary rather than competitive, but its AVIA and AutoHCS platforms are emerging AI-driven HCS analytics competitors to Araceli's own Clairvoyance software.

Broad incumbents

• Bruker Cellular Analysis: Acquired Berkeley Lights and operates in cellular analysis including imaging; broader life-science instrumentation player with overlapping but not directly competing HCS offerings.
• Agilent Technologies (Cell Analysis): Major analytical instruments provider with cell analysis offerings (acquired ACEA Biosciences/xCELLigence); competes broadly in the cell-based assay and screening tools market alongside Araceli.
• Sartorius (Essen BioScience / Incucyte): Acquired Essen BioScience (Incucyte live cell imaging); broader bioprocessing-focused supplier with live cell analysis products that intersect with Araceli's Endeavor Live Cell target use cases.

Direct peers

• Molecular Devices (Danaher): Established incumbent in high-content imaging with the ImageXpress product line serving the same pharma/biotech screening workflows as Araceli's Endeavor; closest direct competitor with deeply installed base across pharma HTS centers.
• Thermo Fisher Scientific (CellInsight / ArrayScan): Offers the CellInsight and HCS Studio platforms for high-content imaging; massive incumbent with bundled reagents, assays, and automation — competes with Araceli across the full HCS workflow.
• Yokogawa Electric (CellVoyager / CQ1): Major supplier of high-content screening systems including the CellVoyager series; directly competes with Endeavor Ultra/Pro in pharma drug discovery screening applications.
• Revvity (formerly PerkinElmer Life Sciences): Operates the Opera Phenix high-content screening platform and Columbus image analysis software; direct competitor offering both instruments and analysis tools to the same pharma/biotech customers.

Emerging players

• Cell Signaling Technology (CST): Major reagent provider expanding into high-content imaging and AI-driven analysis; potential emerging competitor with bundled reagent-plus-imaging offerings for the same drug discovery customers.
• Nanolive: Swiss startup developing label-free live cell imaging technology; Araceli's US GM previously led Nanolive — comparable emerging player in the live cell imaging space that could overlap with Endeavor Live Cell.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/araceli-biosciences
• Xx.com/aracelibio

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Araceli Biosciences